pricing model

This page shows the latest pricing model news and features for those working in and with pharma, biotech and healthcare.

News: Charity criticises NHS England and Vertex over Orkambi access, Sema scores again, NodThera launched

based pricing model.

New trial results suggest CAR-T effects are durable in lymphoma

Ultimately, the winning player could be the company that gets the pricing and access model just right and keeps the cost not insignificant production costs of CAR-T under close control.
Daily Brief

A major new study published in Nature Reviews calls for a ‘global revolution’in the pricing of new cancer drugs – and claims an algorithm could turn what some see as the ... The paper, titled Sustainability and affordability of cancer drugs: a
Duchenne UK and pharma partner pilot data-sharing HTA approach

These delays are worsened for diseases as there is often limited evidence available to meet the requirements for access and pricing decisions.”. ... The hope is that the model could also be used for other rare diseases and provide greater certainty
Post-Shkreli KaloBios pledges transparent pricing

The new pricing model "will guide the company's strategy and operations", according to new CEO Cameron Durrant, who has pledged to price its Chagas disease treatment benznidazole on the basis ... Our new pricing model is a commitment to define and
UK pharma's contribution to NHS hits £1bn mark

The AAR was announced by Minister for Life Sciences George Freeman in November 2014 after it became apparent that plans to replace the PPRS with a value-based pricing model - along

More from news
Approximately 0 fully matching, plus 18 partially matching documents found.

Brexit and Trump

that we need to return to servicing a high-volume, low-cost model in consumer healthcare, and a parity pricing model in Rx.
Pharma deals in September 2015

to pursue a “ robust” pricing model. ... Pharmaceuticals. He has also written a letter to employees to assuage their concerns over company's business model, potential exposure and the fall in the company's stock price (it fell
Interview: Richard Bergström, EFPIA

These are good examples of where legislation helps promote innovation, but unfortunately it's the access to markets, pricing and reimbursement that are deteriorating. ... I have worked very closely with the Swedish government to shape value-based-pricing.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

A roadmap to strategic drug pricing

A roadmap to strategic drug pricing. The current unit-based pricing model for drugs is too one-dimensional for the market's present needs. ... Pharma firms must identify products that will benefit from innovative pricing models, and then forge the types

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Home based, Editorial Team Leader, Medical Communications: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Multi-Channel Account Managers - Road / Homebased – Full or Part...: Competitive salary

Home based, Senior Medical Writer, Medical Communications: Excellent package

Add my company

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape: Is it a solution to addressing the challenges of the value-based marketplace?...
Creativity has lost its worth: Creativity has lost its worth, and sadly it is undermining effectiveness...